@majorajay.bsky.social

@cuhematology.bsky.social @cudeptofmedicine.bsky.social

Be on the lookout for a manuscript next year further describing our work! Big thanks to @ASH_hematology for allowing me to present and my mentor @majorajay for all the guidance and support!

Check out for more info:
- ashpublications.org/blood/article/…
- bison-pro.org

We plan to further expand this work by modeling pt cohorts at higher risk for inferior QoL outcomes, using the heatmap model to potentially detect those pts at risk for relapse/tx failure, and further examining the impact of novel txs in different disease states #ASH24 /9

Taken together, this proof-of-principle study demonstrates we can successfully utilize the BISON-PRO study group to detect meaningful differences between groups of lymphoma pts receiving different treatments/monitoring #ASH24 /8

Similar improvements in reducing negative QoL outcomes were observed for active treatment groups at 6 months. Pts receiving cell therapies had temporary worsening of anxiety/depression early in tx but did have improvement in fatigue in our cohort #ASH24 /7

For the positive outcomes, surveillance pts saw minimal changes from 0 to 6 months. Pts receiving systemic tx or cell therapies had overall improved measures at 6 mos., but pts receiving chemo had worsened cognitive function at 6 months #ASH24 /6

Once we observed these differences, we used these PROMIS T-scores to calculate percentiles and use the relative change in T-score percentiles from baseline to various time points to construct a heatmap model of positive and negative QoL measures #ASH24 /5

Similarly, PROMIS instruments were able to detect differences between groups, and here we highlight that global physical health and role functioning were higher in patients undergoing active surveillance vs active tx #ASH24 /4

Using FACT instruments, we observed significant differences between groups at baseline for lymphoma pts. Interestingly, QoL seemingly improved for pts with lymphoma undergoing active tx (FACT-LYM), but this was not seen with CLL pts (FACT-LEU) #ASH24 /3

In our initial feasibility study, we administered PROMIS and FACT instruments to patients in 3 arms longitudinally and sought to determine if we could detect meaningful differences between study groups #ASH24 /2